



Novel Therapies against *Mycobacterium tuberculosis*

Guest Editor:

Prof. Dr. Vishwanath Venketaraman

Microbiology/Immunology,
Department of Basic Medical
Sciences, College of Osteopathic
Medicine of the Pacific, Western
University of Health Sciences,
Pomona, CA, USA

venketaraman@westernu.edu

Deadline for manuscript
submissions:

15 December 2022

Message from the Guest Editor

Dear Colleagues,

Thanks to the unprecedented pandemic caused by SARS-CoV-2, especially its delta and omicron variants, infections caused by *Mycobacterium tuberculosis* (*M. tb*) have not been adequately diagnosed and managed since 2020 due to overwhelmed health care systems. Pathogens such as *M. tb* have been around for several thousand years and are still causing significant morbidity and mortality, especially in developing countries. Effective strategies to prevent, diagnose, and manage *M. tb* infection will greatly reduce morbidity and mortality among children and individuals with weakened immune systems, such as those with HIV and type 2 diabetes. We therefore invite research and review articles for this Special Issue on preclinical and clinical research findings that shed light on the mechanistic details of host–pathogen interactions, molecular pathogenesis, and host-directed therapies, on the development of vaccines and therapeutic agents against mycobacterial infections, and on strategies to diagnose and effectively manage the disease.

